| October 03, 2005 |
Notification of conclusion of exclusive distribution agreement with Micrus Corporation. |
|
 |
|
As of 30th September, 2005, Goodman has entered into an exclusive distribution
agreement for the domestic market of Japan with John Kilcoyne (CEO) of
Micrus Endovascular Corporation (hereafter referred to as Micrus), an American
cerebral aneurysm treatment device manufacturer. |
|
|
|
Exclusive distribution agreement goals and contents
|
|
Goodman's business activities to date have focused on the import, development,
manufacture and sales of intravascular diagnostic and therapeutic products
used in the field of interventional cardiology. In order to internally
develop devices that employ cutting edge technology, Goodman made an intensive
investment of managerial resources by purchasing two US companies (Avantec
Vascular, LightLab Imaging) in 2005.
Meanwhile, in
order to expand into the interventional neurology and radiology fields for
which future market growth is expected, I.R. Medical Laboratory was established
as a subsidiary company of Goodman in July of 2005.
Micrus is a developer and manufacturer of devices for use in coil embolization
therapy, a popular percutaneous neurovascular treatment (for cerebral aneurysms).
Superior features of the 3 dimensional coil include: conforming well to
the shape of the aneurysm, therein preventing gaps from developing post-implantation;
an exceptionally short detachment time when implanting the micro coil.
Micrus coils are approved by the FDA for the United States and have procured
CE marking for the European market, achieving large success in both markets.
It is expected that government approval will be obtained in the near future
for sales within Japan.
The synergy created from having entered into agreement with Micrus for
exclusive distribution and having purchased I.R. Medical, along with the
superiority of the product, ensures an environment for future success.
It is expected that Goodman will be able to establish a significant position
within the field of neurovascular treatment. |
|
|
|
1. Exclusive distribution contents |
|
|
1)Content
|
Exclusive distribution agreement within the domestic Japanese market |
| 2)Product |
3 dimensional
Microcoil, delivery system, full product line |
| 3)Agreement term |
Commencing 30
September, 2005, for a period of five (5) years, extended automatically for one
(1) year periods. |
|
|
|
|
2. Micrus Corporate overview |
|
| 1)Trading name |
Micrus Endovascular Corporation |
| 2)Primary business interest |
Development,
production, distribution of micro coils for neurovascular treatment |
| 3)Established |
June, 1996 |
| 4)Head Office location |
Sunnyvale, California, USA |
| 5)CEO |
John Kilcoyne |
| 6)Public traded |
June, 2005 |
|
|
|
|
3. Distribution commencement period |
|
Expected to commence November, 2005 |
|
|
|
4. Sales performance forecast |
|
Sales expected to exceed 3,000,000,000 yen after 3 years. |
|
|
|
